Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

Benzinga · 2d ago
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.75 to $8.